Colorectal cancer screening test
Behavioraldelivery of colorectal cancer screening test by GP
NCT Number: NCT06664567
In this registry-based cluster randomized controlled trial, we will assess the impact of a proactive strategy of general practitioners (GP) who will systematically provide screening kits of colorectal cancer (CRC) to all patients of even age (50, 52, 54...up to 74 years) versus usual practice where the eligible population receive an invitation letter to visit the general practitioner and receive the screening kit.
Trial opening soon.
Get Notified50 year–74 year
All sexes
Observational
Colorectal cancer is one of the leading causes of cancer and death in France in both men and women. The generalized screening rate is about 30% in France, far from the expected 65%, despite the fact that screening is free and a letter of invitation is sent to the individual's home, and despite the financial incentives provided to the practitioner. Different studies have looked for the causes of non-implementation by the individual: negligence, "dirty"; forgetfulness, and the practitioner: organizational problem, communication problem. A few intervention studies have been carried out with little success: sending the invitation to the individual's home, sending a letter of reminder, sending a letter of general information on screening to the practitioner, sending the list of patients who have not taken the test to the practitioner allows for a few percent improvement in screening. In this registry-based cluster randomized controlled trial, we will assess the impact of a proactive strategy of general practitioners who will systematically provide screening kits of colorectal cancer to all patients of even age (50, 52, 54 years...up to 74 years) versus usual practice where the eligible population receive an invitation letter to visit the general practitioner and receive the screening kit. The screening rate will be calculated for each arm at the end of the 2-year study with data from the health insurance.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
delivery of colorectal cancer screening test by GP
Time frame: 2 years after the start of protocol
The primary endpoint of this trial is the rate of participation rate in CRC screening in the eligible patient population grouped with or without intervention. This criterion will be measured by retrospective analysis of retrospective analysis of National Health Data System data.
Time frame: 2 years after the start of protocol
Rate of patients with positive test results
Time frame: 2 years after the start of protocol
rate of patients tested positive at an early stage
Time frame: 2 years after the start of protocol
rate of patients testing positive at a late stage
Contact information is provided by the study sponsor or research team.
Christele BLANC-BISSON, Dr
CONTACT
05 56 65 55 00 ext. +33
Pierre POULIZAC
CONTACT
05 57 82 08 49 ext. +33
University Hospital, Bordeaux
Other
Impact of a Proactive Strategy of General Practitioners on CRC Screening: a Registry-based Cluster-based Randomized Controlled Trial
Acronym: DECORE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07738939
Adenocarcinoma, Biliary Tract Cancer (BTC)
Los Angeles, California, United States
View Trial DetailsNCT07730489
Colonic Diseases, Colorectal Cancer
Shenyang, Liaoning, China
View Trial DetailsNCT06414122
Colonic Diseases, Colorectal Cancer
Cologne, North Rhine-Westphalia, Germany
View Trial DetailsNCT07094893
Colonic Diseases, Colorectal Cancer
View Trial Details